Ascent Therapeutics is pioneering a new class of drugs called PepducinsTM.
Pepducins are a breakthrough approach to targeting G-protein coupled receptors (GPCRs)
on the inside surface of the cell membrane, dramatically expanding the GPCR frontier.
GPCRs are critically involved in a wide variety of serious illnesses, including inflammation,
cancer, CNS disorders and cardiovascular disease. Pepducin technology represents an exciting new area
of research directed towards a well-validated class of drug targets.
